Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Določanje mutacij v genih c-KIT in PDGFRA pri bolnikih z gastrointestinalnimi stromalnimi tumorji
Authors:ID Grgić, Marina (Author)
ID Novaković, Srdjan (Author)
Files:.pdf PDF - Presentation file, download (492,46 KB)
MD5: 80E0DF2CE292337E723845F726CD036B
PID: 20.500.12556/dirros/eddb6cd2-a6a1-478a-b3bf-61add87bf2b4
 
Language:Slovenian
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Na Oddelku za molekularno diagnostiko Onkološkega inštituta Ljubljana smo uvedli testiranje mutacij v protoonkogenih c-KIT in PDGFRA z metodo neposrednega sekvenciranja. Uporaba zaviralcev tirozin kinaz za zdravljenje bolnikov z gastrointestinalnimi stromalnimi tumorji (GIST) je omogočila uspešnejše zdravljenje. Na izbiro najustreznejšega zdravila za bolnike z GIST vplivajo aktivacijske mutacije v genih c-KIT in PDGFRA. Mutacije v navedenih genih najdemo pri približno 90 % bolnikov z GIST. Večina izmed teh mutacij omogoči dober odgovor na zdravljenje z zaviralci tirozin kinaz (npr. imatinibom v prvi liniji zdravljenja), nekatere izmed mutacij pa povzročijo neodzivnost bolnika na zdravljenje. Pogosto se pojavijo tudi sekundarne mutacije, ki kljub prvotnemu dobremu odgovoru na zdravljenje z zaviralci tirozin kinaz povzročijo neodzivnost bolnika na prvotno zdravilo. V tem primeru je treba izbrati drugo vrsto zaviralca tirozin kinaz (npr. sunitinib, sorafenib, nilotinib). Poznavanje mutacijskega statusa genov c-KIT in PDGFRA predstavlja pomemben podatek za zdravnika pri izbiri ustreznega zdravljenja za posameznega bolnika.
Keywords:rak prebavil, mutacije, geni, testi
Publication status:Published
Publication version:Version of Record
Year of publishing:2014
Number of pages:str. 9-12, 72
Numbering:Letn. 18, št. 1
PID:20.500.12556/DiRROS-8635 New window
UDC:616-006
ISSN on article:1408-1741
URN:URN:NBN:SI:doc-38L5UIRA
COBISS.SI-ID:1806971 New window
Copyright:by Authors
Publication date in DiRROS:31.08.2018
Views:3753
Downloads:914
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:[Identification of c-KIT and PDGFRA gene mutations in patients with gastrointestinal stromal tumours]
Abstract:At the Institute of Oncology Ljubljana, the Department of Molecular Diagnostics introduced testing of mutations in the c-KIT and PDGFRA proto-oncogenes using the direct sequencing method. The use of tyrosine kinase inhibitors to treat patients with gastrointestinal stromal tumours (GIST) enables a more successful treatment. Selection of the most appropriate drug for patients with GIST depends on the activation mutations in the c-KIT and PDGFRA genes. Mutations in these genes are found in approximately 90% of patients with GIST. The majority of these mutations show a good response to treatment with tyrosine kinase inhibitors (e.g. imatinib in the first-line treatment), while some mutations cause the patient to become unresponsive to treatment. Secondary mutations are also common, which cause patient’s lack of response to the original drug despite the originally good response to treatment with tyrosine kinase inhibitors. In this case, it is necessary to choose a different type of tyrosine kinase inhibitor (e.g. sunitinib, sorafenib, nilotinib). Identification of the c-KIT and PDGFRA gene mutation status represents important information for the doctor when deciding on the appropriate treatment for individual patients.


Archive

niGradiv

Back